Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 ALPHAEON Acquires Specialty Omega-3 Developer - Nutraceuticals World

What are you searching for?

Sign in
Market Updates

ALPHAEON Acquires Specialty Omega-3 Developer

Author Image

By: Sean Moloughney

Editor, Nutraceuticals World

ALPHAEON Corporation, Irvine, CA, has acquired Physician Recommended Nutriceuticals (PRN), a developer of specialty omega-3s and related products for dry eye and macular degeneration, based in Plymouth Meeting, PA, in a transaction worth up to $55 million.

“ALPHAEON’s acquisition of PRN brings together world renowned ophthalmologists and a premier physician recommended line of nutraceutical products that benefit patients,” said ALPHAEON CEO Robert Grant. “Over the past 5 years, PRN has established a strong leadership position in the rapidly growing field of evidence-based physician recommended and dispensed nutraceuticals, achieving consistently high double-digit growth over several years. We are very pleased to partner with such a quality organization and leadership team and look forward to maintaining their stand-alone operation just outside of Philadelphia, PA. This acquisition brings significant customer synergies to both organizations and is ideally aligned to ALPHAEON’s mission to provide best-in-class wellness related products to patients.”

PRN’s dry eye patent-pending formula has the highest bioavailable concentration per serving of purified omega-3 fatty acids and the optimal ratio of 3:1 EPA/DHA, according to the company. Studies have shown Dry Eye Omega Benefits addresses the inflammation leading to dry eye and improve the recovery time from refractive and cataract surgery. In a dry eye clinical study, 82% of patients who consumed PRN’s re-esterified triglyceride (rTG) omega-3 product for an eight-week period had a positive change in the composition of their meibum, a potential root cause of dry-eye syndrome.

Add us as a preferred source on Google

Get the latest Nutraceuticals World news, insights and analysis in your Google Search and AI experiences.

Add Nutraceuticals World as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters

Topics